Study Results: Safety Data
Objective The primary safety outcome was assessment of all adverse events.
• No Serious Peri-Procedural Events
• Serious device/procedure events through 18 months:
-Worsening of pre-existing proteinuria (n=1) -Symptomatic hypotension (n=1) -Worsening of pre-existing renal artery stenosis and new stenotic lesion (n=2 events in 1 patient)
The EnligHTN System delivers renal denervation with no serious peri-procedural events and an acceptable safety profile through 18 months 
